San Gabriel, California Clinical Trials

The goal of this study is to further develop a non-invasive prenatal blood test that can diagnose genetic disorders in the fetus by looking at fetal DNA (genetic material) found in the mother's bloodstream during pregnancy. Women carrying a fetus diagnosed with microdeletions/microduplications (small missing or extra pieces of DNA ...

Using the Centers for Medicare and Medicaid (CMS) Medicare Research Identifiable Files (RIFs) containing all medical claims for 100% of Medicare beneficiaries enrolled in the Medicare fee-for-service program, claims-based patient history and demographics will be combined with longitudinal analyses. In this study, the control group will include all patients receiving ...

This study is a randomized controlled trial (RCT) to test the health benefits of an education and peer mentor support intervention. Chinese American breast cancer survivors who have completed primary treatment will be randomly assigned to either the intervention group or a control group to receive enhanced usual care while ...

A 5 day trial evaluating Favipiravir (oral medication) vs. placebo in patients with the Flu.

A one year, phase 3 study for adults with COPD.

A one year, phase 3 study for adults with moderate to severe COPD who have a history of COPD exacerbations.

A one year, phase 3 study for adults with Asthma who are not well controlled with inhaled corticosteroids.

This is a Phase 2, randomized, open-label study to evaluate efficacy and safety of oral vadadustat for the treatment of anemia in hemodialysis participants converting from epoetin alfa therapy. The study will be conducted in two parts running in parallel: Part 1, Main Study in a hemodialysis population on maintenance ...

This is an open-label, non-randomized, Phase 1b study to evaluate the safety, pharmacokinetics (PK) profiles, and preliminary evidence of antitumor activity of PTC299 and the metabolite, O-desmethyl PTC299, in participants with relapsed/refractory acute myeloid leukemia (AML) who have exhausted standard available therapies known to provide clinical benefit. The study is ...

This study includes an Open-Label and a Double-Blind component. In each, there is an up to 28 days screen period followed by a treatment period of 52 weeks and a 4 week end of treatment assessment.